Synaffix Wins ‘Best ADC Platform Technology’ Award Again at World ADC Awards Ceremony 2022

AMSTERDAM, NETHERLANDS – 15th September 2022 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that the Company was awarded ‘Best ADC Platform Technology’ at the World ADC Conference 2022.

This marks the second time that Synaffix’ groundbreaking ADC platform technology has been acknowledged as industry-leading by winning 1^st place in this award category. The 2022 World ADC Awards finalists were shortlisted through a voting pool of over 2,500 individuals, with a panel of distinguished, independent world-renowned ADC experts assessing each finalist to decide the winners.

Synaffix’ proprietary ADC technology platform consists of GlycoConnect™, HydraSpace™ and toxSYN™ technologies.  These technologies are aimed at enabling best-in-class ADCs from any antibody, with significantly enhanced efficacy and tolerability. 

Prof. Floris van Delft, CSO of Synaffix, said: “We are thrilled to have won the ‘Best ADC Technology Platform’ Award again. This appreciation shown by our industry peers is testament to the creativity and skills of our scientific team that has developed our proprietary best-in-class ADC platform. It’s fantastic to see that our technology is now being used to develop 18 different targeted cancer therapeutics across 10 collaborations with top-tier biotech and pharma companies, potentially leading to better cures for cancer patients.  We would not be at this stage without our partners and are very grateful for their continued trust and support.”